Indivior Pharmaceuticals, Inc.
Could not find a ticker for this position, may be a filing error
A specialty pharmaceutical company focused on treating opioid addiction, Indivior makes Suboxone (a film that dissolves under the tongue) and Sublocade (a once-monthly injection) to help people recover, plus Opvee, a nasal spray that reverses opioid overdoses. It began in 1994 as a buprenorphine unit inside consumer-goods giant Reckitt Benckiser, then spun off in 2014 to become its own company. Its name is widely read as a nod to "individual" recovery—caring for the person, not just the condition.
Granted 1.27M
Granted 93.3K · Sold 36.0K
Granted 101.5K · Sold 18.6K
Granted 79.9K
Granted 10.4K
Granted 6.5K
Granted 24.3K · Bought 1.5K
Granted 6.5K
Granted 6.5K
Granted 6.5K
Granted 6.5K · Bought 39
Granted 6.5K · Bought 940
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Ciaffoni JosephChief Executive Officer, Director · 2 transactions | +481.2% | 790.3K | 1.27M | — | — |
| Preblick RyanChief Financial Officer · 5 transactions | -10.4% | 284.8K | 93.3K | — | 36.0K |
| Heidbreder ChristianChief Scientific Officer · 3 transactions | +19.5% | 227.9K | 101.5K | — | 18.6K |
| Burris Jeffrey WChief Legal Officer · 2 transactions | +158.6% | 71.5K | 79.9K | — | — |
| Wheadon David E.Director · 1 transaction | +51.3% | 30.8K | 10.4K | — | — |
| Thompson JulietDirector · 2 transactions | +23.5% | 28.4K | 6.5K | — | — |
| Anderson Woodrow DChief Accounting Officer · 5 transactions | +144.7% | 27.6K | 24.3K | 1.5K | — |
| Ninivaggi Daniel ADirector · 1 transaction | +31.6% | 27.2K | 6.5K | — | — |
| Stejbach MarkDirector · 1 transaction | +31.7% | 27.1K | 6.5K | — | — |
| Humphreys KeithDirector · 1 transaction | +68.4% | 16.0K | 6.5K | — | — |
| Ryan BarbaraDirector · 3 transactions | +115.3% | 12.2K | 6.5K | 39 | — |
| Kingsley Stuart ADirector · 2 transactions | +160.7% | 12.1K | 6.5K | 940 | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -52.1K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.